Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 61, Issue 4, Pages 319-326Publisher
ELSEVIER
DOI: 10.1016/j.addr.2009.01.001
Keywords
Reactive oxygen species; Catalase, Targeted delivery; Liver; Receptor-mediated endocytosis; PEGylation; Tumor metastasis
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan
Ask authors/readers for more resources
Reactive oxygen species (ROS) have been suggested to be involved in a variety of human diseases. Catalase, an enzyme degrading hydrogen peroxide, can be used as a therapeutic agent for such diseases, but its successful application will depend on the distribution of the enzyme to the sites where ROS are generated. Chemical modification techniques have been used to control the tissue distribution of catalase, and delivery to hepatocytes (galactosylation), liver nonparenchymal cells (mannosylation or succinylation), kidney (cationization) and the blood pool (PEGylation) has been achieved. The effectiveness of catalase delivery has been demonstrated in animal models for hepatic ischemia/reperfusion injury, chemical-induced tissue injuries and tumor metastasis to the liver, lung and peritoneal organs. Significant inhibition was observed in the ROS-mediated oxidative tissue damages and ROS-mediated upregulation of expression of genes responsible for recruitment of inflammatory cells and for metastatic growth of tumor cells. Because oxygen plays a fundamental key role in our life and oxidative stress is implicated in a wide variety of human diseases, catalase delivery could have wide application in the near future. (C) 2009 Elsevier B.V. All rights reserved
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available